- In April 2025, Revvity, Inc. received FDA approval for its Auto-Pure 2400 liquid handling platform integrated with the T-SPOT.TB test. This automation enhances laboratory workflows by processing up to 24 samples per run in under 3.5 hours, aiming to improve latent tuberculosis detection efficiency
- In February 2025, QIAGEN secured a favorable court decision from the German Federal Patent Court, reaffirming the validity of a key patent protecting innovations in its QuantiFERON-TB Gold Plus technology. This legal victory strengthens QIAGEN's intellectual property rights in the IGRA market
- In June 2024, The American Academy of Pediatrics updated its guidelines to recommend the use of IGRA tests, such as QIAGEN's QuantiFERON-TB Gold Plus, for screening latent tuberculosis infections in at-risk children of all ages. This endorsement is expected to increase the adoption of IGRAs in pediatric population
- In August 2024, The World Health Organization issued a public call for data to inform an update of its guidance on the use of IGRAs for detecting tuberculosis infection. This initiative aims to assess new IGRA technologies and their role in global TB control strategies
- In January 2022, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beijing Wantai’s TB-IGRA and Qiagen QuantiFERON-TB Gold Plus products. This expands the range of tests available to detect TB infection
